Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1998-06-11
1999-11-02
Jarvis, William R. A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
A61K 31535
Patent
active
059771046
ABSTRACT:
The present invention provides methods for the treatment or prevention of bipolar disorder without concomitant therapy with other antidepressant or anti-anxiety agents which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.
REFERENCES:
patent: 5162339 (1992-11-01), Lowe, II
patent: 5496833 (1996-03-01), Baker et al.
patent: 5538982 (1996-07-01), Hagan et al.
patent: 5612337 (1997-03-01), Baker et al.
patent: 5716942 (1998-02-01), Dorn et al.
patent: 5719147 (1998-02-01), Dorn et al.
patent: 5728695 (1998-03-01), Harrison et al.
Aguiar, M., et al., Physiology & Behavior, 1996, 60(4) 1183-1186.
Barden, N., et al., J. Neurochem., 1983, 41, 834-840.
Brodin, E., et al., Neuropharmacology, 1987, 26(6) 581-590.
Brodin, E., et al., Neuropeptides, 1994, 26, 253-280.
Culman, J., et al., J. Physiol. Pharmacol., 1995, 73, 885-891.
Cutler, et al., J. Psychopharmacol, 1994, 8, A22, 87.
Elliott, P. J., Exp. Brain Res. UK, 1988, 73, 354-356.
F-D-C ReportsPrescription Pharamceuticals and Biotechnology, Dec. 8, 1997, 59 (49), 10.
File, S. E., Pharm. Biochem. Behavior, 1997, 58,3, 747-752.
Kramer, et al., Science, 1998, 281, 1640-1645.
Lowe, J., et al., Drug News Perspect, 1992, 5 (4), 223.
Malek-Ahmadi, Neuroscience and Behavorial Reviews, 1992, 16, 365-359.
Rimon, R., et al., Biological Psychiatry, 1984, 19 (4), 509-516.
Roccon, et al., Pharmacological Research, 1995, 31, 191.
Shaikh, M., et al., Brain Research, 1993, 625, 283-294.
Shirayama, Y., et al., Brain Research, 1996, 739, 70-78.
Siegel, R., et al., Neurochem. Int., 1984, 6 (6), 783-789.
Siegel, A., et al., Aggressive Behavior, 1995, 21, 49-62.
Teixeira, R., et al., European J. Pharm., 1996, 311, 7-14.
Vassout, et al., Neuropeptides, 1994, 26 (Suppl. 1), 38.
Wahlestedt, Science, 1998, 281, 1624-1625.
Wall Street Journal, Aug. 13, 1998, B1, Col. 2.
Baker Raymond
Curtis Neil Roy
Elliott Jason Matthew
Harrison Timothy
Hollingworth Gregory John
Jarvis William R. A.
Merck Sharp & Dohme Ltd.
Rose David L.
Thies J. Eric
LandOfFree
Use of NK-1 receptor antagonists for treating bipolar disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of NK-1 receptor antagonists for treating bipolar disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of NK-1 receptor antagonists for treating bipolar disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2135699